Grifols Biologicals is developing a plasmapheresis technique that infuses patients with human albumin and intravenous immunoglobin (IVIG) for the treatment of Alzheimer's disease.

Grifols reports that treated patients with moderate Alzheimer’s experienced a 61% reduction in disease progression and a 71% reduction of symptoms, with positive results reported for both moderate and mild Alzheimer’s.